Merck Expands Singapore Lab with Advanced Biosafety Testing Capabilities

Merck is expanding its biosafety testing laboratory in Singapore to provide advanced services for customers across the Asia Pacific region. The lab will now offer both Cell Line Characterization services and GMP next-generation sequencing (NGS) capabilities, making it the first BioReliance facility in Asia-Pacific to do so.

The expanded facility aims to support the industry's move towards state-of-the-art quality control testing of biologics and 3Rs (Replacement, Reduction, and Refinement of animal use). Merck's Singapore laboratory will also offer advanced molecular methods including Blazar, a proprietary platform for rapid virus detection.

'Localizing these BioReliance testing capabilities means our Asia Pacific biopharma customers can accelerate their development timelines, improve operational efficiency, and meet evolving regulatory and sustainability standards,' said Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck.